[1]潘东 罗勇.沙库巴曲缬沙坦在心力衰竭治疗中的研究进展[J].心血管病学进展,2020,(2):114-117.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.003]
　PAN DongLUO Yong.Sacubitril/valsartan in the Treatment of Heart Failure[J].Advances in Cardiovascular Diseases,2020,(2):114-117.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.003]
点击复制

沙库巴曲缬沙坦在心力衰竭治疗中的研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2020年2期
页码:
114-117
栏目:
综述
出版日期:
2020-02-25

文章信息/Info

Title:
Sacubitril/valsartan in the Treatment of Heart Failure
作者:
潘东 罗勇
(川北医学院附属医院,四川 南充 637000 )
Author(s):
PAN DongLUO Yong
(Affiliated Hospital of North Sichuan Medical College, Nanchong 637000 , Sichuan, China)
关键词:
沙库巴曲缬沙坦; 血管紧张素受体-脑啡肽酶抑制剂; 心力衰竭
Keywords:
Sacubitril/valsartan;  Angiotensin receptor neprilysin inhibitor; Heart failure
DOI:
10.16806/j.cnki.issn.1004-3934.2020.02.003
摘要:
心力衰竭是各类心脏疾病的终末阶段，既往尽管使用了临床指南推荐的治疗，心力衰竭患者的愈后仍欠佳。血管紧张素受体-脑啡肽酶抑制剂沙库巴曲缬沙坦是一种新型的治疗心力衰竭药物，因其卓越的疗效，越来越受到人们关注，现就沙库巴曲缬沙坦作用机制、临床研究结果、临床指南推荐及使用方案等方面做一阐述。
Abstract:
Heart failure is the end stage of various kinds of heart diseases. Although the treatment recommended by the clinical guidelines has been used, The treatment effect of heart failure is still unsatisfactory. Angiotensin receptor neprilysin inhibitor sacubitril/valsartan is a new type of heart failure treatment drug.Due to its excellent curative effect, it has attracted more and more attention.In this article,the mechanism,clinical research results, clinical guidelines recommendation and adminstration plan were discussed.

参考文献/References:

[1] 张健,张宇辉.射血分数保留的心力衰竭治疗进展[J].心血管病学进展,2019,40(02):161-165.

[2] Raj L, Adhyaru B. An evidence-based review of recent advances in therapy for heart failure with reduced ejection fraction (HFrEF)[J]. Postgraduate Medical Journal,2016,92(1094):726-734.

[3] 陈伟伟,高润霖,刘力生,等.《中国心血管病报告2016》概要[J].中国循环杂志,2017,32(06):521-530.

[4] Shearer F, Lang CC, Struthers AD. Renin-angiotensin-aldosterone system inhibitors in heart failure[J]. Clin Pharmacol Ther,2013,94(4):459-467.

[5] Yandrapalli S, Aronow WS, Mondal P, et al. The evolution of natriuretic peptide augmentation in management of heart failure and the role of sacubitril/valsartan[J]. Archives of Medical Science Ams,2017,13(5):1207-1216.

[6] Buggey J, Mentz RJ, Devore AD, et al. Angiotensin receptor neprilysin inhibition in heart failure: mechanistic action and clinical impact[J]. J Card Fail,21(9):S47893007.

[7] Fu S, Ping P, Wang F, et al. Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure[J]. J Biol Eng,12(1):2.

[8] Senni M, Mcmurray JJ, Wachter R, et al. Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens[J]. Eur J Heart Fail,2016,18(9):1193-1202.

[9] Menendez JT. The mechanism of action of LCZ696[J]. Card Fail Rev,2016,2(1):40-46.

[10] Yandrapalli S, Andries G, Biswas M, et al. Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives[J]. Vasc Health Risk Manag,2017,13:369-382.

[11] Hegde LG, Yu C, Madhavi C, et al. Comparative efficacy of AHU-377, a potent neprilysin inhibitor, in two rat models of volume-dependent hypertension[J]. Bmc Pharmacology,2011,11(1):1-2.

[12] Almufleh A, Marbach J, Chih S, et al. Ejection fraction improvement and reverse remodeling achieved with Sacubitril/Valsartan in heart failure with reduced ejection fraction patients[J]. Am J Cardiovasc Dis,2017,7(6):108-113.

[13] Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.[J]. Lancet,2012,380(9851):1387-1395.

[14] Solomon SD, Rizkala AR, Gong J, et al. Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rationale and design of the PARAGON-HF trial[J]. JACC Heart Fail,2017,5(7):471-482.

[15] Solomon SD, Rizkala AR, Gong J, et al. PARAGON-HF-angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction[J]. JACC?Heart?Fail,?2017,5(7):471-482.

[16] Mcmurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure[J].N Engl J Med,2014,371(11):993-1004.

[17] 崔晓通,周京敏,葛均波. PARADIGM-HF研究结果解读[J]. 中国循环杂志,2018,33(2):203-205.

[18] Velazquez EJ, Morrow DA, Devore AD, et al. Angiotensin-neprilysin inhibition in acute decompensated heart failure[J]. N Engl J Med,2019,380(6):539-548.

[19] Wachter R, Senni M, Belohlavek J, et al. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study[J]. Eur J Heart Failure,2019,21(8):998-1007.

[20] Wachter R,Pascual-Figal D, Belohlavek J, et al. Initiation of sacubitril/valsartan and optimisation of evidence-based heart failure therapies after hospitalisation for acute decompensated heart failure: An analysis of the TRANSITION study. Poster presentation (P773) at ESC Congress 2019, Paris France.

[21] Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America[J]. Circulation,2017,136(6):e137-e161.

[22] Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America[J]. Circulation,2016,134(13):e282-e293.

[23] Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Rev Esp Cardiol (Engl Ed),2016,69(12):1167.

[24] Ezekowitz J A, O’Meara E, Mcdonald M A, et al. 2017 comprehensive update of the canadian cardiovascular society guidelines for the management of heart failure[J]. Canadian Journal of Cardiology,2017,33(11):1342.

[25] 中华心血管病杂志编辑委员会中华医学会心血管病分会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志,2018,46(10):769-789.

[26] Correction to: 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America[J]. Circulation,2016,134(13):e298.

[27] Shaddy R, Canter C, Halnon N, et al. Design for the sacubitril/valsartan (LCZ696) compared with enalapril study of pediatric patients with heart failure due to systemic left ventricle systolic dysfunction (PANORAMA-HF study)[J]. Am Heart J,2017,193:23-34.

[28] Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2016 update: a report from the american heart association[J]. Circulation,2016,133(4):e38-e360.

[29] Gaziano TA, Fonarow GC, Claggett B, et al. Cost-effectiveness analysis of sacubitril/valsartan vs enalapril in patients with heart failure and reduced ejection fraction[J]. JAMA Cardiology,2016,1(6):666.

[30] Correale M, Monaco I, Ferraretti A, et al. Hospitalization cost reduction with sacubitril-valsartan implementation in a cohort of patients from the Daunia Heart Failure Registry[J]. Int J Cardiol?Heart?Vasc,2019,22:102-104.

[31] King JB, Shah RU, Bress AP, et al. Cost-effectiveness of sacubitril-valsartan combination therapy compared with enalapril for the treatment of heart failure with reduced ejection fraction[J]. JACC Heart Fail,2016,4(5):392-402.

[32] Albert NM, Swindle JP, Buysman EK, et al. Lower hospitalization and healthcare costs with sacubitril/valsartan versus angiotensin‐converting enzyme inhibitor or angiotensin‐receptor blocker in a retrospective analysis of patients with heart failure[J]. J Am Heart Assoc,2019,8(9):e011089.

[33] Cook C, Cole G, Asaria P, et al. The annual global economic burden of heart failure[J]. Int J Cardiol,2014,171(3):368-376.

相似文献/References:

[1]朱永翔 李烽 张耀庭 陆丽洁 龙明智.沙库巴曲缬沙坦在射血分数降低性心力衰竭患者治疗中的研究进展[J].心血管病学进展,2019,(9):1249.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.016]
　ZHU Yongxiang,LI Feng,ZHANG Yaoting,et al.Sacubitril-valsartan for Heart Failure with Reduced Ejection Fraction[J].Advances in Cardiovascular Diseases,2019,(2):1249.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.016]
[2]费美莹 姜东炬.心力衰竭药物沙库巴曲缬沙坦的研究进展[J].心血管病学进展,2020,(2):122.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.005]
　FEI Meiying J IANG Dongju.Heart Failure Drug Sacubitril Valsartan[J].Advances in Cardiovascular Diseases,2020,(2):122.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.005]
[3]程家元 殷跃辉.沙库巴曲缬沙坦在心血管疾病中的临床应用与展望[J].心血管病学进展,2020,(9):914.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.007]
　CHENG Jiayuan YIN Yuehui.Clinical Application and Prospect of Sacubitril Valsartan in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2020,(2):914.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.007]
[4]王晓旭,羊镇宇.沙库巴曲缬沙坦在血压治疗中的研究进展[J].心血管病学进展,2021,(2):138.[doi:10.16806/j.cnki.issn.1004-3934.20.02.011]
　WANG Xiaoxu,YANG Zhenyu.Advances in the Study of LCZ696 in Hypertension[J].Advances in Cardiovascular Diseases,2021,(2):138.[doi:10.16806/j.cnki.issn.1004-3934.20.02.011]
[5]穆耶赛尔·玉苏普 芦颜美 汤宝鹏.沙库巴曲缬沙坦对心力衰竭患者认知功能的影响[J].心血管病学进展,2023,(8):709.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.009]
　Muyassar·Yusup,LU Yanmei,TANG Baopeng.Effect of Sacubritil/Valsartan on Cognitive Function in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2023,(2):709.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.009]

更新日期/Last Update: 2020-04-14